Paid Clinical Trials for Carcinoma, Hepatocellular

Showing all 6 results

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

by CTG

in Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Carcinoma, Pleural Effusion, Malignant, Ascites, Malignant

Other

California

Deadline:

07/01/2028

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

by CTG

in Carcinoma, Hepatocellular

Other

Arizona

Deadline:

12/31/2029

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

by CTG

in Carcinoma, Hepatocellular

Other

California

Deadline:

02/28/2026

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

by CTG

in Carcinoma, Hepatocellular, Liver Cell Carcinoma

Other

New Jersey

Deadline:

06/01/2027

Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

by CTG

in Carcinoma, Hepatocellular

Other

Texas

Deadline:

12/01/2026

National Liver Cancer Screening Trial

by CTG

in Liver Cirrhosis, Liver Cancer, Carcinoma, Hepatocellular, Hepatitis B

Other

California

Deadline:

12/31/2034

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

National Liver Cancer Screening Trial

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Carcinoma, Hepatocellular

Filter Results:

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

National Liver Cancer Screening Trial

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps